Clorox Co (CLX) Stake Lessened by Wedbush Securities Inc.
Wedbush Securities Inc. trimmed its position in shares of Clorox Co (NYSE:CLX) by 2.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,090 shares of the company’s stock after selling 109 shares during the quarter. Wedbush Securities Inc.’s holdings in Clorox were worth $817,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Clorox by 7.7% during the fourth quarter. BlackRock Inc. now owns 10,555,837 shares of the company’s stock worth $1,627,074,000 after acquiring an additional 752,085 shares during the period. Oregon Public Employees Retirement Fund increased its stake in shares of Clorox by 48,033.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,808,980 shares of the company’s stock worth $44,000 after acquiring an additional 6,794,834 shares during the period. Morgan Stanley increased its stake in shares of Clorox by 178.2% during the third quarter. Morgan Stanley now owns 3,063,813 shares of the company’s stock worth $460,828,000 after acquiring an additional 1,962,433 shares during the period. Northern Trust Corp increased its stake in shares of Clorox by 2.8% during the fourth quarter. Northern Trust Corp now owns 2,278,268 shares of the company’s stock worth $351,173,000 after acquiring an additional 61,663 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Clorox by 21.5% during the fourth quarter. Geode Capital Management LLC now owns 1,899,544 shares of the company’s stock worth $292,347,000 after acquiring an additional 335,835 shares during the period. Institutional investors and hedge funds own 76.90% of the company’s stock.
Shares of NYSE CLX opened at $153.48 on Friday. Clorox Co has a 12-month low of $113.57 and a 12-month high of $167.70. The stock has a market capitalization of $19.67 billion, a price-to-earnings ratio of 24.52, a price-to-earnings-growth ratio of 3.86 and a beta of 0.32. The company has a current ratio of 1.15, a quick ratio of 0.66 and a debt-to-equity ratio of 3.08.
The firm also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Wednesday, April 24th will be issued a $0.96 dividend. This represents a $3.84 annualized dividend and a dividend yield of 2.50%. The ex-dividend date is Tuesday, April 23rd. Clorox’s dividend payout ratio (DPR) is presently 61.34%.
A number of analysts recently commented on CLX shares. Zacks Investment Research downgraded shares of Clorox from a “hold” rating to a “sell” rating in a report on Tuesday. JPMorgan Chase & Co. downgraded shares of Clorox from a “neutral” rating to an “underweight” rating and decreased their price objective for the stock from $159.00 to $139.00 in a report on Monday, April 8th. Credit Suisse Group started coverage on shares of Clorox in a report on Wednesday, March 6th. They set an “outperform” rating and a $172.00 price objective on the stock. Wells Fargo & Co reissued a “hold” rating and set a $157.00 price objective on shares of Clorox in a report on Thursday, February 21st. Finally, Barclays reissued a “hold” rating and set a $142.00 price objective on shares of Clorox in a report on Wednesday, February 6th. Six equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $151.21.
In other news, SVP Matthew T. Laszlo sold 10,585 shares of the business’s stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $153.89, for a total value of $1,628,925.65. Following the completion of the transaction, the senior vice president now owns 17,994 shares of the company’s stock, valued at $2,769,096.66. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Andrew J. Mowery sold 5,340 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $156.44, for a total transaction of $835,389.60. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Featured Story: Roth IRA
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.